Reduction of iron-regulated amyloid precursor protein and β-amyloid peptide by (-)-epigallocatechin-3-gallate in cell cultures: Implications for iron chelation in Alzheimer's disease

Journal of Neurochemistry

Volumn 97, Issue 2, 2006, Pages 527-536

  Reznichenko, L ^a   Amit, T ^a   Zheng, H ^b   Avramovich Tirosh, Y ^a   Youdim, M B H ^a   Weinreb, O ^a   Mandel, S ^a,c  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^c NONE   (Israel)

Author keywords

( ) epigallocatechin 3 gallate; Alzheimer's disease; Hypoxia; Neurodegeneration; Neuroprotection; Two dimensional gel electrophoresis

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CHELATING AGENT; DEFEROXAMINE; EPIGALLOCATECHIN GALLATE; FERROUS SULFATE; MESSENGER RNA; POLYPHENOL; SCAVENGER; TRANSFERRIN;

5' UNTRANSLATED REGION; ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENCY; FEMALE; HUMAN; HUMAN CELL; IRON CHELATION; IRON METABOLISM; MUTATION; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; REPORTER GENE; RNA TRANSLATION; TEA; TRANSCRIPTION REGULATION; TWO DIMENSIONAL GEL ELECTROPHORESIS;

AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTIGENS, CD; BLOTTING, WESTERN; CATECHIN; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CRICETULUS; DEFEROXAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; GENE EXPRESSION; HUMANS; IMMUNOPRECIPITATION; IRON; IRON CHELATING AGENTS; NEUROBLASTOMA; NEUROPROTECTIVE AGENTS; RECEPTORS, TRANSFERRIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSFECTION;

ANIMALIA; CRICETULUS GRISEUS;

EID: 33645294934     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2006.03770.x     Document Type: Article

References (63)

1. Atwood C. S. Obrenovich M. E. Liu T. Chan H. Perry G. Smith M. A. Martins R. N. 2003 Amyloid-beta: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-beta. Brain Res. Brain Res. Rev. 43 1 16.
2. Bar-Am O. Weinreb O. Amit T. Youdim M. B. 2005 Regulation of Bcl-2 family proteins, neurotrophic factors and APP Processing in the neurorescue activity of N-Propargylamine. FASEB J. 19 1899 1901.
3. Baum L. Ng A. 2004 Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer's disease animal models. J. Alzheimers Dis. 6 367 377 ; discussion 443 369.
4. Beard J. L. Connor J. R. Jones B. C. 1993 Iron in the brain. Nutr. Rev. 51 157 170.
5. Ben-Shachar D. Eshel G. Finberg J. P. Youdim M. B. 1991 The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J. Neurochem. 56 1441 1444.
6. Cai X. D. Golde T. E. Younkin S. G. 1993 Release of excess amyloid beta protein from a mutant amyloid beta protein precursor. Science 259 514 516.
7. Cao X. Sudhof T. C. 2001 A transcriptionally [correction of transcriptively] active complex of APP with Fe65 and histone acetyltransferase Tip60. Science 293 115 120.
8. Cherny R. A. Atwood C. S. Xilinas M. E. et al. q14 2001 Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30 665 676.
9. Citron M. Oltersdorf T. Haass C. McConlogue L. Hung A. Y. Seubert P. Vigo-Pelfrey C. Lieberburg I. Selkoe D. J. 1992 Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature 360 672 674.
10. da Cruz e Silva E. F. da Cruz e Silva O. A. 2003 Protein phosphorylation and APP metabolism. Neurochem. Res. 28 1553 1561.
11. Cuajungco M. P. Frederickson C. J. Bush A. I. 2005 Amyloid-beta metal interaction and metal chelation. Subcell. Biochem. 38 235 254.
12. De Strooper B. Annaert W. 2000 Proteolytic processing and cell biological functions of the amyloid precursor protein. J. Cell Sci. 113 1857 1870.
13. Dinis T. C. Maderia V. M. Almeida L. M. 1994 Action of phenolic derivatives (acetaminophen, salicylate, and 5-aminosalicylate) as inhibitors of membrane lipid peroxidation and as peroxyl radical scavengers. Arch. Biochem. Biophys. 315 161 169.
14. Esler W. P. Wolfe M. S. 2001 A portrait of Alzheimer secretases - new features and familiar faces. Science 293 1449 1454.
15. Gal S. Zheng H. Fridkin M. Youdim M. B. 2005 Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. J. Neurochem. 95 79 88.
16. Gao Y. Pimplikar S. W. 2001 The gamma-secretase-cleaved C-terminal fragment of amyloid precursor protein mediates signaling to the nucleus. Proc. Natl Acad. Sci. USA 98 14 979 14 984.
17. Grinberg L. N. Newmark H. Kitrossky N. Rahamim E. Chevion M. Rachmilewitz E. A. 1997 Protective effects of tea polyphenols against oxidative damage to red blood cells. Biochem. Pharmacol. 54 973 978.
18. Guo Q. Zhao B. Li M. Shen S. Xin W. 1996 Studies on protective mechanisms of four components of green tea polyphenols against lipid peroxidation in synaptosomes. Biochim. Biophys. Acta 1304 210 222.
19. Hanson E. S. Rawlins M. L. Leibold E. A. 2003 Oxygen and iron regulation of iron regulatory protein 2. J. Biol. Chem. 278 40 337 40 342.
20. Hider R. C. Liu Z. D. Khodr H. H. 2001 Metal chelation of polyphenols. Methods Enzymol. 335 190 203.
21. Honda K. Smith M. A. Zhu X. et al. 2005 Ribosomal RNA in Alzheimer disease is oxidized by bound redox-active iron. J. Biol. Chem. 280 20 978 20 986.
22. Huang X. Moir R. D. Tanzi R. E. Bush A. I. Rogers J. T. 2004 Redox-active metals, oxidative stress, and Alzheimer's disease pathology. Ann. N. Y. Acad. Sci. 1012 153 163.
23. Jellinger K. A. 2003 Neuropathological spectrum of synucleinopathies. Mov. Disord 18 S2 S12.
24. Joseph J. A. Shukitt-Hale B. Casadesus G. 2005 Reversing the deleterious effects of aging on neuronal communication and behavior: beneficial properties of fruit polyphenolic compounds. Am. J. Clin. Nutr. 81 313S 316S.
25. Kaur D. Yantiri F. Rajagopalan S. et al. 2003 Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 37 899 909.
26. Kumamoto M. Sonda T. Nagayama K. Tabata M. 2001 Effects of pH and metal ions on antioxidative activities of catechins. Biosci. Biotechnol. Biochem. 65 126 132.
27. Leissring M. A. Murphy M. P. Mead T. R. et al. 2002 A physiologic signaling role for the gamma-secretase-derived intracellular fragment of APP. Proc. Natl Acad. Sci. USA 99 4697 4702.
28. Levites Y. Amit T. Mandel S. Youdim M. B. H. 2003 Neuroprotection and neurorescue against amyloid beta toxicity and PKC-dependent release of non-amyloidogenic soluble precusor protein by green tea polyphenol (-)-epigallocatechin-3-gallate. FASEB J. 17 952 954.
29. Levites Y. Weinreb O. Maor G. Youdim M. B. H. Mandel S. 2001 Green tea polyphenol (-)- epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced dopaminergic neurodegeneration. J. Neurochem. 78 1073 1082.
30. Levites Y. Amit T. Youdim M. B. H. Mandel S. 2002 Involvement of protein kinase C activation and cell survival/cell cycle genes in green tea polyphenol (-)-epigallocatechin-3-gallate neuroprotective action. J. Biol. Chem. 277 30 574 30 580.
31. Mandel S. Maor G. Youdim M. B. H. 2004a Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate. J. Mol. Neurosci. 24 401 416.
32. Mandel S. Weinreb O. Amit T. Youdim M. B. H. 2004b Cell Signaling pathways in the neuroprotective actions of the green tea polyphenol (-)-epigallocatechin-3-gallate: implications for neurodegenerative diseases. J. Neurochem. 88 1555 1569.
33. Mandel S. A. Avramovich-Tirosh Y. Reznichenko L. Zheng H. Weinreb O. Amit T. Youdim M. B. 2005 Multifunctional activities of green tea catechins in neuroprotection. Neurosignals 14 46 60.
34. Mattson M. P. 1997 Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol. Rev. 77 1081 1132.
35. Meade T. W. 1975 Subacute myelo-optic neuropathy and clioquinol. An epidemiological case-history for diagnosis. Br. J. Prev. Soc. Med. 29 157 169.
36. Moos T. Morgan E. H. 2004 The metabolism of neuronal iron and its pathogenic role in neurological disease: review. Ann. N. Y. Acad. Sci. 1012 14 26.
37. Morel I. Lescoat G. Cogrel P. Sergent O. Pasdeloup N. Brissot P. Cillard P. Cillard J. 1999 Antioxidant and iron-chelating activities of the flavonoids catechin, quercetin and diosmetin on iron-loaded rat hepatocyte cultures. Biochem. Pharmacol. 45 13 19.
38. Payton S. Cahill C. M. Randall J. D. Gullans S. R. Rogers J. T. 2003 Drug discovery targeted to the Alzheimer's APP mRNA 5′-untranslated region: the action of paroxetine and dimercaptopropanol. J. Mol. Neurosci. 20 267 275.
39. Perez R. G. Squazzo S. L. Koo E. H. 1996 Enhanced release of amyloid beta-protein from codon 670/671 'Swedish' mutant beta-amyloid precursor protein occurs in both secretory and endocytic pathways. J. Biol. Chem. 271 9100 9107.
40. Rezai-Zadeh K. Shytle D. Sun N. et al. 2005 Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J. Neurosci. 25 8807 8814.
41. Reznichenko L. Amit T. Youdim M. B. Mandel S. 2005 Green tea polyphenol (-)-epigallocatechin-3-gallate induces neurorescue of long-term serum-deprived PC12 cells and promotes neurite outgrowth. J. Neurochem. 2005 1157 1167.
42. Rice-Evans C. 2001 Flavonoid antioxidants. Curr. Med. Chem. 8 797 807.
43. Richardson D. R. 2004 Novel chelators for central nervous system disorders that involve alterations in the metabolism of iron and other metal ions. Ann. N. Y. Acad. Sci. 1012 326 341.
44. Rogers J. T. Lahiri D. K. 2004 Metal and inflammatory targets for Alzheimer's disease. Curr. Drug Targets 5 535 551.
45. Rogers J. T. Randall J. D. Cahill C. M. et al. 2002 An iron-responsive element type II in the 5′-untranslated region of the Alzheimer's amyloid precursor protein transcript. J. Biol. Chem. 277 45 518 45 528.
46. Sadrzadeh S. M. Saffari Y. 2004 Iron and brain disorders. Am. J. Clin. Pathol. 121 S64 S70.
47. Sharp F. R. Bernaudin M. 2004 HIF1 and oxygen sensing in the brain. Nat. Rev. Neurosci. 5 437 448.
48. Shaw K. T. Utsuki T. Rogers J. YuQ. S. Sambamurti K. Brossi A. Ge Y. W. Lahiri D. K. Greig N. H. 2001 Phenserine regulates translation of beta-amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development. Proc. Natl Acad. Sci. USA 98 7605 7610.
49. Simons M. Tienari P. J. Dotti C. G. Beyreuther K. 1995 Two-dimensional gel mapping of the processing of the human amyloid precursor protein in rat hippocampal neurons. FEBS Lett. 368 363 366.
50. Sipe J. C. Lee P. Beutler E. 2002 Brain iron metabolism and neurodegenerative disorders. Dev. Neurosci. 24 188 196.
51. 3H](-)-epigallocatechin gallate, a cancer preventive tea polyphenol, in mouse tissue. Carcinogenesis 19 1771 1776.
52. Templeton D. M. Liu Y. 2003 Genetic regulation of cell function in response to iron overload or chelation. Biochim. Biophys. Acta 1619 113 124.
53. Thomas R. Kim M. H. 2005 Epigallocatechin gallate inhibits HIF-1alpha degradation in prostate cancer cells. Biochem. Biophys. Res. Commun. 334 543 548.
54. Wang J. Chen G. Muckenthaler M. Galy B. Hentze M. W. Pantopoulos K. 2004 Iron-mediated degradation of IRP2, an unexpected pathway involving a 2-oxoglutarate-dependent oxygenase activity. Mol. Cell. Biol. 24 954 965.
55. Weinreb O. Mandel S. Youdim M. B. H. 2003 cDNA gene expression profile homology of antioxidants and their anti-apoptotic and pro-apoptotic activities in human neuroblastoma cells. FASEB J. 17 935 937.
56. Xia W. Zhang J. Perez R. Koo E. H. Selkoe D. J. 1997 Interaction between amyloid precursor protein and presenilins in mammalian cells: implications for the pathogenesis of Alzheimer disease. Proc. Natl Acad. Sci. USA 94 8208 8213.
57. Yogev-Falach M. Amit T. Bar-Am. O. Youdim M. B. 2003 The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives in MAPK-dependent amyloid precursor protein processing. FASEB J. 17 2325 2327.
58. Youdim M. B. H. Buccafusco J. J. 2005 Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol. Sci. 26 27 35.
59. Youdim M. B. H. Riederer P. 2003 Iron in the brain, normal and pathological, in Encyclopedia of Neuroscience Adelman G. Smith B., eds). Elsevier Science BV. Amsterdamq16.
60. Zecca L. Youdim M. B. Riederer P. Connor J. R. Crichton R. R. 2004 Iron, brain ageing and neurodegenerative disorders. Nat. Rev. Neurosci. 5 863 873.
61. Zheng H. Gal S. Weiner L. M. Bar-Am. O. Warshawsky A. Fridkin M. Youdim M. B. 2005a Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J. Neurochem. 95 68 78.
62. Zheng H. Weiner L. M. Bar-Am. O. Epsztejn S. Cabantchik Z. I. Warshawsky A. Youdim M. B. Fridkin M. 2005b Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. Bioorg. Med. Chem. 13 773 783.
63. Zhou Y. D. Kim Y. P. Li X. C. Baerson S. R. Agarwal A. K. Hodges T. W. Ferreira D. Nagle D. G. 2004 Hypoxia-inducible factor-1 activation by (-)-epicatechin gallate: potential adverse effects of cancer chemoprevention with high-dose green tea extracts. J. Nat. Prod. 67 2063 2069.